Benjamin Graham taught that Intelligent Investors must do a thorough fundamental analysis of investment opportunities to determine their intrinsic value and inherent risk. Â This isÂ best done by utilizing a systematic approach to analysis that will provide investors with a sense of how a specific company compares to another companyÂ or by reviewing theÂ 5 Undervalued Companies for the Defensive Investor Near 52 Week Lows.Â Â By using theÂ ModernGraham methodÂ one can review a company’s historical accomplishments and determine an intrinsic value that can be compared across industries. Â What follows is a specific look at how Covidien PLC (COV)Â fares in theÂ ModernGraham valuation model.
Company ProfileÂ (obtained fromÂ Google Finance):Â Covidien Public Limited Company is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings. The Company operates its businesses through three segments: Medical Devices, which includes the development, manufacture and sale of endomechanical instruments, energy devices, soft tissue repair products, vascular products, oximetry and monitoring products, airway and ventilation products and other medical products; Pharmaceuticals, which includes the development, manufacture and distribution of specialty pharmaceuticals, active pharmaceutical ingredients, contrast products and radiopharmaceuticals., and Medical Supplies, which includes the development, manufacture and sale of nursing care products. In February 2014, the Company announced that it has completed the acquisition of Given Imaging Ltd. Effective March 28, 2014, Covidien PLC acquired New Wave Surgical Corp, a manufacturer of medical devices.
Defensive Investor – must pass at least 6 of the following 7 tests: Score = 3/7
- Adequate Size of Enterprise – market capitalization of at least $2 billion – PASS
- Sufficiently Strong Financial Condition – current ratio greater than 2 -Â PASS
- Earnings Stability – positive earnings per share for at least 10 straight years – FAIL
- Dividend Record – has paid a dividend for at least 10 straight years – FAIL
- Earnings Growth – earnings per share has increased by at least 1/3 over the last 10 years using 3 year averages at beginning and end of period – PASS
- Moderate PEmg ratio – PEmg is less than 20 -Â FAIL
- Moderate Price to Assets – PB ratio is less than 2.5 or PB x PEmg is less than 50 – FAIL
Enterprising Investor – must pass at least 4 of the following 5 tests or be suitable for a defensive investor: Score = 4/5
- Sufficiently Strong Financial Condition, Part 1 – current ratio greater than 1.5 – PASS
- Sufficiently Strong Financial Condition, Part 2 – Debt to Net Current Assets ratio less than 1.1 – FAIL
- Earnings Stability – positive earnings per share for at least 5 years – PASS
- Dividend Record – currently pays a dividend – PASS
- Earnings growth – EPSmg greater than 5 years ago – PASS
|MG Opinion||Fairly Valued|
|Value Based on 3% Growth||$53.79|
|Value Based on 0% Growth||$31.53|
|Market Implied Growth Rate||8.07%|
|Net Current Asset Value (NCAV)||-$12.35|
Balance Sheet – 3/28/2014
Earnings Per Share
Earnings Per Share – ModernGraham
Covidien will be acquired by Medtronic in the very near future, in a fair deal. Â Medtronic is assuming the role of an Enterprising Investor, as Covidien qualifies for that investor type but not the Defensive Investor. Â The Defensive Investor has concerns with the lack of earnings stability over the last ten years, the lack of a strong dividend history, and the high PEmg and PB ratios at this time, while the Enterprising Investor is only concerned by the high level of debt relative to the net current assets. Â As for a valuation, the company appears fairly valued at the price Medtronic is offering, after growing its EPSmg (normalized earnings) from $2.18 in 2010 to an estimated $3.71 for 2014. Â This level of demonstrated growth supports the market’s implied estimate of 8.07% earnings growth and leads theÂ ModernGrahamÂ valuation model, based on Benjamin Graham’s formula, to return an estimate of intrinsic value falling within a margin of safety in relation toÂ the price.
Be sure to check out theÂ previousÂ ModernGraham valuations of Covidien (COV)Â for more perspective! Â It should be noted that if acquisition is completed as anticipated, this will be the finalÂ ModernGraham valuation of Covidien as a stand-alone company.
The next part of the analysis is up to individual investors, and requires discussion of the company’s prospects. Â What do you think? Â What value would you put on Covidien (COV)? Â Where do you see the company going in the future? Â Is there a company you like better? Â Leave aÂ comment on ourÂ Facebook pageÂ or mentionÂ @ModernGrahamÂ on Twitter to discuss.
Disclaimer: Â The author did not hold a position in Covidien (COV)Â orÂ in any other company mentioned in this article at the time of publication and had no intention of changing that position within the next 72 hours. Â Logo taken from wikipedia for the sole purpose of identifying the company; this article is not affiliated with the company in any manner.